Effect of the Increasing Use of Piperacillin/Tazobactam on the Incidence of Vancomycin-Resistant Enterococci in Four Academic Medical Centers
Open Access
- 1 May 2004
- journal article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 25 (5), 380-383
- https://doi.org/10.1086/502409
Abstract
Background: : The substitution of piperacillin/tazobactam, ampicillin/sulbactam, or both for third-generation cephalosporins has been associated with reduced vancomycin-resistant enterococci (VRE). However, piperacillin/tazobactam came into widespread use during a period in which the prevalence of VRE increased. We hypothesized that the increasing use of piperacillin/tazobactam and other agents with relatively enhanced anti-enterococcal activity (ie, piperacillin, ampicillin/sulbactam, and ampicillin) has been associated with increased or unchanged rates of VRE in some hospitals.Design: : We retrospectively evaluated the correlation between hospital antibiotic use (defined daily doses per 10,000 patient-days of care) and incidence of stool or non-stool VRE isolation. We assessed whether a high or increasing proportion of use of beta-lactam agents with relatively enhanced versus minimal (ie, third-generation cephalosporins and ticarcillin/clavulanate) anti-enterococcal activity would prevent increased VRE.Setting: : Four academic medical centers.Results: : With the increasing use of piperacillin/tazobactam, the use of beta-lactam agents with enhanced activity against enterococci surpassed the combined use of third-generation cephalosporins and ticarcillin/clavulanate in each hospital. In one hospital, the incidence of VRE was positively correlated with the use of piperacillin/tazobactam or beta-lactam agents with enhanced anti-enterococcal activity (P< .0001). The incidence of VRE rose steadily in another hospital despite relatively high use of beta-lactam agents with enhanced versus minimal anti-enterococcal activity. A negative correlation between VRE and piperacillin/tazobactam or beta-lactam agents with enhanced anti-enterococcal activity was observed in one hospital, but this correlation was not statistically significant.Conclusion: : Increasing the hospital use of piperacillin/tazobactam and other beta-lactams with relatively enhanced anti-enterococcal activity may not be an effective control measure for VRE.Keywords
This publication has 10 references indexed in Scilit:
- Effects of Antibiotics on Nosocomial Epidemiology of Vancomycin-Resistant EnterococciAntimicrobial Agents and Chemotherapy, 2002
- Parallel Analysis of Individual and Aggregated Data on Antibiotic Exposure and Resistance in Gram‐Negative BacilliClinical Infectious Diseases, 2001
- Effect of Antibiotic Therapy on the Density of Vancomycin-Resistant Enterococci in the Stool of Colonized PatientsNew England Journal of Medicine, 2000
- REDUCTION OF VANCOMYCIN-RESISTANT ENTEROCOCCAL INFECTIONS BY LIMITATION OF BROAD-SPECTRUM CEPHALOSPORIN USE IN A TRAUMA AND BURN INTENSIVE CARE UNITShock, 2000
- Effect of Parenteral Antibiotic Administration on the Establishment of Colonization with Vancomycin‐ResistantEnterococcus faeciumin the Mouse Gastrointestinal TractThe Journal of Infectious Diseases, 2000
- Decreased Antimicrobial Resistance Following Changes in Antibiotic UseSurgical Infections, 2000
- Infection-Control Measures Reduce Transmission of Vancomycin-Resistant Enterococci in an Endemic SettingAnnals of Internal Medicine, 1999
- Effect of Parenteral Antibiotic Administration on Persistence of Vancomycin‐ResistantEnterococcus faeciumin the Mouse Gastrointestinal TractThe Journal of Infectious Diseases, 1999
- The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usageJournal of Antimicrobial Chemotherapy, 1999
- Manipulation of a Hospital Antimicrobial Formulary to Control an Outbreak of Vancomycin-Resistant EnterococciClinical Infectious Diseases, 1996